The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

NAFAZATROM     5-methyl-2-(2-naphthalen-2- yloxyethyl)-4H...

Synonyms: Nafazatromum, CHEMBL8425, Bay-g-6575, SureCN93681, Bay-g 6575, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bay-g 6575


High impact information on Bay-g 6575


Chemical compound and disease context of Bay-g 6575


Biological context of Bay-g 6575


Anatomical context of Bay-g 6575


Associations of Bay-g 6575 with other chemical compounds


Gene context of Bay-g 6575


Analytical, diagnostic and therapeutic context of Bay-g 6575


  1. Role of lipoxygenase products in murine pulmonary granuloma formation. Kunkel, S.L., Chensue, S.W., Mouton, C., Higashi, G.I. J. Clin. Invest. (1984) [Pubmed]
  2. Nafazatrom in treatment of thrombotic thrombocytopenic purpura. Durrant, S.T., Joosten, P., Gordon-Smith, E.C. Lancet (1985) [Pubmed]
  3. Nafazatrom in thrombocytopenic purpura. Copplestone, J.A., Worsley, A., Sadullah, S., Hamblin, T.J. Lancet (1986) [Pubmed]
  4. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Bednar, M., Smith, B., Pinto, A., Mullane, K.M. Circ. Res. (1985) [Pubmed]
  5. Interference with tumor cell-induced degradation of endothelial matrix on the antimetastatic action of nafazatrom. Maniglia, C.A., Loulakis, P.P., Sartorelli, A.C. J. Natl. Cancer Inst. (1986) [Pubmed]
  6. Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound. Vermylen, J., Chamone, D.A., Verstraete, M. Lancet (1979) [Pubmed]
  7. Beneficial effects of nafazatrom on ischemic reperfused myocardium. Shea, M.J., Murtagh, J.J., Jolly, S.R., Abrams, G.D., Pitt, B., Lucchesi, B.R. Eur. J. Pharmacol. (1984) [Pubmed]
  8. Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract. Nigam, S., Zakrzewicz, A., Eskafi, S., Roscher, A. Cancer Metastasis Rev. (1992) [Pubmed]
  9. The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia. Fiedler, V.B. Basic Res. Cardiol. (1983) [Pubmed]
  10. Free radicals and myocardial ischemia and reperfusion injury. Simpson, P.J., Lucchesi, B.R. J. Lab. Clin. Med. (1987) [Pubmed]
  11. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Marnett, L.J., Siedlik, P.H., Ochs, R.C., Pagels, W.R., Das, M., Honn, K.V., Warnock, R.H., Tainer, B.E., Eling, T.E. Mol. Pharmacol. (1984) [Pubmed]
  12. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds. Coker, S.J., Parratt, J.R. J. Mol. Cell. Cardiol. (1984) [Pubmed]
  13. The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury. Fiedler, V.B., Mardin, M., Perzborn, E., Grützmann, R. Naunyn Schmiedebergs Arch. Pharmacol. (1985) [Pubmed]
  14. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease. Roy, L., Mehta, J., Mehta, P. Am. Heart J. (1985) [Pubmed]
  15. Oral nafazatrom in man: effect on inhaled antigen challenge. Fuller, R.W., Maltby, N., Richmond, R., Dollery, C.T., Taylor, G.W., Ritter, W., Philipp, E. British journal of clinical pharmacology. (1987) [Pubmed]
  16. Platelet survival and function in animals with prosthetic mitral valve: the effect of nafazatrom. Al-Mondhiry, H., Pierce, W.S., Richenbacher, W. Thromb. Haemost. (1984) [Pubmed]
  17. Nafazatrom: in-vitro assessment of radiation and drug activity against animal and human cell lines. Haas, J.S., Haas, C.D., Kyle, G.W. Investigational new drugs. (1984) [Pubmed]
  18. Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575). Strasser, T., Fischer, S., Weber, P.C. Biochem. Pharmacol. (1985) [Pubmed]
  19. Evidence for a dual pathway in platelet activating factor-induced aggregation of rat polymorphonuclear leucocytes. Moodley, I., Stuttle, A. Prostaglandins (1987) [Pubmed]
  20. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine. Massad, L., Plotkine, M., Boulu, R.G. Thromb. Res. (1988) [Pubmed]
  21. The lipoxygenase inhibitor nafazatrom inhibits stimulated prolactin secretion in cultured rat lactotrophs (GH4C1 cells). Bjøro, T., Larsen, V., Englund, K., Torjesen, P.A., Haug, E. Scand. J. Clin. Lab. Invest. (1992) [Pubmed]
  22. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase. Wong, P.Y., Chao, P.H., McGiff, J.C. J. Pharmacol. Exp. Ther. (1982) [Pubmed]
  23. In vivo and in vitro effects of nafazatrom (Bay g 6575), an antithrombotic compound, on arachidonic acid metabolism in platelets and vascular tissue. Fischer, S., Struppler, M., Weber, P.C. Biochem. Pharmacol. (1983) [Pubmed]
  24. Reaction of the antithrombotic and antimetastatic agent, nafazatrom, with oxidizing radicals. Sevilla, M.D., Neta, P., Marnett, L.J. Biochem. Biophys. Res. Commun. (1983) [Pubmed]
  25. Mechanism of nafazatrom-induced inhibition of rat uterus contractions in vitro. Cantabrana, B., Velasco, G., Andrès-Trelles, F., Hidalgo, A. Archives internationales de pharmacodynamie et de thérapie. (1989) [Pubmed]
  26. Lipoxygenase inhibitor nafazatrom fails to attenuate postischaemic ventricular dysfunction. O'Neill, P.G., Charlat, M.L., Kim, H.S., Pocius, J., Michael, L.H., Hartley, C.J., Zhu, W.X., Roberts, R., Bolli, R. Cardiovasc. Res. (1987) [Pubmed]
  27. Determination of nafazatrom in body fluids by high-performance thin-layer chromatography with post-chromatographic derivatization. Ritter, W. J. Chromatogr. (1984) [Pubmed]
  28. Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat. Fiedler, V.B. Eur. J. Pharmacol. (1983) [Pubmed]
WikiGenes - Universities